Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

by Jabbour, E., Kantarjian, H.M., Saglio, G., Steegmann, J.L., Shah, N.P., Boqué, C., Chuah, C., Pavlovsky, C., Mayer, J., Cortes, J., Baccarani, M., Kim, D.-W., Bradley-Garelik, M.B., Mohamed, H., Wildgust, M., Hochhaus, A.
Published 2016

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens

by Rassidakis, G.Z, Herold, N, Myrberg, I.H, Tsesmetzis, N, Rudd, S.G, Henter, J.-I, Schaller, T, Ng, S.-B, Chng, W.J, Yan, B, Ng, C.H, Ravandi, F, Andreeff, M, Kantarjian, H.M, Medeiros, L.J, Xagoraris, I, Khoury, J.D
Published 2020